for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Alkermes Plc

ALKS.OQ

Latest Trade

18.44USD

Change

0.29(+1.60%)

Volume

181,923

Today's Range

18.15

 - 

18.79

52 Week Range

17.11

 - 

42.65

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
18.15
Open
18.28
Volume
181,923
3M AVG Volume
26.12
Today's High
18.79
Today's Low
18.15
52 Week High
42.65
52 Week Low
17.11
Shares Out (MIL)
157.13
Market Cap (MIL)
2,851.92
Forward P/E
54.20
Dividend (Yield %)
--

Next Event

Q3 2019 Alkermes Plc Earnings Call

Latest Developments

More

Alkermes PLC Says Received Notice From FDA Of Tentative Approval Of Vumerity

Alkermes Announces Settlement With Amneal Over Vivitrol Patent Dispute

Alkermes Q2 Non-GAAP Earnings Per Share $0.09

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Alkermes Plc

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

Industry

Biotechnology & Drugs

Contact Info

Connaught HSE, 1 Burlington Road

+353.1.7728000

http://www.alkermes.com

Executive Leadership

Richard F. Pops

Chairman of the Board, Chief Executive Officer

James M. Frates

Chief Financial Officer, Senior Vice President, Treasurer

Iain M. Brown

Senior Vice President - Finance, Chief Accounting Officer

David Joseph Gaffin

Senior Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

Michael J. Landine

Senior Vice President - Corporate Development, Chief Risk Officer

Key Stats

2.67 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.7K

2017

0.9K

2018

1.1K

2019(E)

1.2K
EPS (USD)

2016

-0.200

2017

0.170

2018

0.610

2019(E)

0.335
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.67
Price To Book (MRQ)
2.61
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
25.50
LT Debt To Equity (MRQ)
25.24
Return on Investment (TTM)
-12.67
Return on Equity (TTM)
-10.42

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up